Your browser doesn't support javascript.
loading
Pharmacodynamics of natalizumab extended interval dosing in MS.
Zhovtis Ryerson, Lana; Li, Xiaochun; Goldberg, Judith D; Hoyt, Tamara; Christensen, Angel; Metzger, Ryan R; Kister, Ilya; Foley, John.
Afiliación
  • Zhovtis Ryerson L; From NYU Multiple Sclerosis Comprehensive Care Center (L.Z.R., I.K.), New York; Division of Biostatistics (X.L., J.D.G.), New York University School of Medicine; and Rocky Mountain MS Research Group (T.H., A.C., R.R.M., J.F.), Salt Lake City, UT. Lana.zhovtisryerson@nyumc.org.
  • Li X; From NYU Multiple Sclerosis Comprehensive Care Center (L.Z.R., I.K.), New York; Division of Biostatistics (X.L., J.D.G.), New York University School of Medicine; and Rocky Mountain MS Research Group (T.H., A.C., R.R.M., J.F.), Salt Lake City, UT.
  • Goldberg JD; From NYU Multiple Sclerosis Comprehensive Care Center (L.Z.R., I.K.), New York; Division of Biostatistics (X.L., J.D.G.), New York University School of Medicine; and Rocky Mountain MS Research Group (T.H., A.C., R.R.M., J.F.), Salt Lake City, UT.
  • Hoyt T; From NYU Multiple Sclerosis Comprehensive Care Center (L.Z.R., I.K.), New York; Division of Biostatistics (X.L., J.D.G.), New York University School of Medicine; and Rocky Mountain MS Research Group (T.H., A.C., R.R.M., J.F.), Salt Lake City, UT.
  • Christensen A; From NYU Multiple Sclerosis Comprehensive Care Center (L.Z.R., I.K.), New York; Division of Biostatistics (X.L., J.D.G.), New York University School of Medicine; and Rocky Mountain MS Research Group (T.H., A.C., R.R.M., J.F.), Salt Lake City, UT.
  • Metzger RR; From NYU Multiple Sclerosis Comprehensive Care Center (L.Z.R., I.K.), New York; Division of Biostatistics (X.L., J.D.G.), New York University School of Medicine; and Rocky Mountain MS Research Group (T.H., A.C., R.R.M., J.F.), Salt Lake City, UT.
  • Kister I; From NYU Multiple Sclerosis Comprehensive Care Center (L.Z.R., I.K.), New York; Division of Biostatistics (X.L., J.D.G.), New York University School of Medicine; and Rocky Mountain MS Research Group (T.H., A.C., R.R.M., J.F.), Salt Lake City, UT.
  • Foley J; From NYU Multiple Sclerosis Comprehensive Care Center (L.Z.R., I.K.), New York; Division of Biostatistics (X.L., J.D.G.), New York University School of Medicine; and Rocky Mountain MS Research Group (T.H., A.C., R.R.M., J.F.), Salt Lake City, UT.
Neurol Neuroimmunol Neuroinflamm ; 7(2)2020 03.
Article en En | MEDLINE | ID: mdl-32019876
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Índice de Masa Corporal / Natalizumab / Factores Inmunológicos / Esclerosis Múltiple Tipo de estudio: Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Neurol Neuroimmunol Neuroinflamm Año: 2020 Tipo del documento: Article Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Índice de Masa Corporal / Natalizumab / Factores Inmunológicos / Esclerosis Múltiple Tipo de estudio: Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Neurol Neuroimmunol Neuroinflamm Año: 2020 Tipo del documento: Article Pais de publicación: Estados Unidos